Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/x2tKSHAZrKY/226029.php
Saturday, May 21, 2011
PolyMedix PMX-30063 Defensin-Mimetic Antibiotic Compound Shows Promising Activity For Oral Mucositis
PolyMedix, Inc. (OTC BB: PYMX), a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study. Oral mucositis is a common and often debilitating inflammation and ulceration that occurs in the mouth as a complication of cancer treatment...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment